) O
, O
( B
22E I
, I
24R I
) I
- I
3 I
beta I
- I
hydroxy I
- I
ergosta I
- I
5 I
, I
22 I
- I
dien I
- I
7 I
- I
one I
( O
6 O
) O
, O
benzoic B
acid I
( O
7 O
) O
, O
methyl B
p I
- I
hydroxybenzoate I
( O
8 O
) O
and O
3 B
, I
4 I
- I
dihydroxybenzoic I
acid I
( O
9 O
) O
. O

Many O
common O
constituents O
were O
found O
in O
both O
species O
, O
including O
shikimic B
acid I
, O
5 B
- I
O I
- I
caffeoylshikimic I
acid I
, O
trans B
- I
resveratrol I
, O
taxifolin B
, O
astilbin B
and O
its O
three O
stereoisomers O
, O
engeletin B
and O
isoengeletin B
. O

beta B
- I
eudesmol I
- O
induced O
apoptosis O
was O
accompanied O
by O
cleavage O
of O
caspase O
- O
3 O
, O
caspase O
- O
9 O
, O
and O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
; O
downregulation O
of O
Bcl O
- O
2 O
expression O
; O
release O
of O
cytochrome O
c O
from O
mitochondria O
; O
and O
decrease O
in O
mitochondrial O
membrane O
potential O
( O
MMP O
) O
. O

Stimulation O
of O
( B
3 I
) I
H I
- I
inositolmonophosphat I
formation O
induced O
by O
i O
. O
c O
. O
v O
. O
injection O
of O
DHPG B
was O
enhanced O
by O
about O
50 O
% O
in O
the O
hippocampus O
of O
cLH O
rats O
. O

Fibroblast O
growth O
factor O
23 O
inhibits O
extrarenal O
synthesis O
of O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
in O
human O
monocytes O
. O

Vitamin B
D I
is O
a O
potent O
stimulator O
of O
monocyte O
innate O
immunity O
, O
and O
this O
effect O
is O
mediated O
via O
intracrine O
conversion O
of O
25 B
- I
hydroxyvitamin I
D I
( O
25OHD B
) O
to O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
( O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
) O
. O

N B
- I
p I
- I
methoxy I
cinnamoyl I
serotonin I
( O
3 O
) O
was O
converted O
into O
its O
O B
- O
demethylated O
compound O
, O
N B
- I
p I
- I
coumaroyl I
serotonin I
( O
2 O
) O
. O

Of O
the O
regioisomeric O
phpy B
' O
s O
, O
2 B
- I
phpy I
behaves O
drastically O
different O
compared O
to O
3 B
- I
and I
4 I
- I
phpy I
. O

For O
2 B
- I
phpy I
, O
C B
- I
H I
bond O
activation O
in O
the O
[ B
NiCl I
( I
phpy I
) I
( I
2 I
) I
] I
( I
+ I
) I
complex O
is O
significant O
, O
whereas O
this O
route O
is O
almost O
suppressed O
for O
the O
corresponding O
complexes O
of O
3 B
- I
and I
4 I
- I
phpy I
and O
only O
occurs O
at O
elevated O
energies O
. O

Dehydrogenation O
of O
lyral B
and O
lilial B
produce O
alpha B
, I
beta I
- I
unsaturated I
aldehydes I
, O
that O
reacts O
with O
lipoic B
acid I
requiring O
proteins O
resulting O
in O
their O
inhibition O
. O

Regarding O
these O
observations O
, O
it O
is O
proposed O
that O
L B
- I
and I
D I
- I
Orn I
function O
differently O
in O
the O
same O
biological O
pathways O
in O
which O
the O
latter O
, O
D B
- I
Orn I
specifically O
regulates O
important O
polyamines B
in O
the O
plant O
cells O
. O

The O
aim O
of O
this O
work O
was O
to O
investigate O
the O
involvement O
of O
serotonin B
( O
5 B
- I
HT I
) O
and O
catecholamines B
, O
as O
well O
as O
the O
role O
of O
glutamatergic O
and O
GABAergic O
cannabinoid O
type O
1 O
( O
CB O
( O
1 O
) O
) O
receptor O
, O
in O
responses O
to O
the O
antidepressant O
- O
like O
doses O
of O
the O
CB O
( O
1 O
) O
receptor O
agonist O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
THC B
) O
and O
the O
antagonist O
rimonabant B
in O
the O
forced O
swim O
test O
( O
FST O
) O
. O

Medium O
and O
high O
oxidation O
state O
metal B
/ I
non I
- I
metal I
fluoride I
and O
oxide B
- O
fluoride B
complexes O
with O
neutral O
donor O
ligands O
. O

While O
most O
high O
and O
medium O
oxidation O
state O
( O
O O
. O
S O
. O
> O
= O
3 O
) O
metal B
and I
non I
- I
metal I
fluorides I
and O
oxide B
fluorides B
are O
strong O
Lewis B
acids I
, O
exploration O
of O
their O
coordination O
chemistry O
with O
neutral O
ligands O
has O
been O
limited O
and O
mostly O
non O
- O
systematic O
. O

MIPEF O
treatments O
, O
conducted O
at O
1 O
. O
2kV O
/ O
cm O
and O
30 O
pulses O
, O
led O
to O
the O
greatest O
increases O
in O
chlorogenic O
( O
152 O
% O
) O
, O
caffeic B
acid I
- I
O I
- I
glucoside I
( O
170 O
% O
) O
and O
caffeic B
( O
140 O
% O
) O
acids O
. O

Vitamin B
D I
is O
a O
fat O
- O
soluble O
precursor O
of O
the O
circulating O
25 B
- I
hydroxyvitamin I
D I
3 I
( O
25 B
( I
OH I
) I
D I
3 I
) O
which O
can O
be O
converted O
by O
the O
1 O
alpha O
- O
hydroxylase O
( O
1 O
alpha O
( O
OH O
) O
ase O
) O
enzyme O
into O
the O
bioactive O
hormonal O
metabolite O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
3 I
( O
1 B
, I
25 I
( I
OH I
) I
2 I
D I
3 I
) O
, O
generally O
known O
to O
promote O
bone O
mineralization O
through O
its O
ability O
to O
enhance O
calcium B
absorption O
from O
the O
gut O
. O

Developmental O
effects O
of O
prenatal O
di B
- I
n I
- I
hexyl I
phthalate I
and O
dicyclohexyl B
phthalate I
exposure O
on O
reproductive O
tract O
of O
male O
rats O
: O
Postnatal O
outcomes O
. O

The O
present O
study O
is O
to O
investigate O
the O
effects O
of O
in O
utero O
di B
- I
n I
- I
hexyl I
phthalate I
( O
DHP B
) O
and O
dicyclohexyl B
phthalate I
exposure O
( O
DCHP B
) O
on O
the O
development O
of O
male O
reproductive O
tract O
at O
prepubertal O
, O
pubertal O
and O
adult O
stages O
. O

Metabolites O
M2 O
and O
M5 O
were O
the O
alcohol B
and O
carboxylic B
acid I
species O
3 B
- I
hydroxypropyl I
- I
phosphinic I
acid I
and O
3 B
- I
hydroxyphosphonoyl I
- I
propanoic I
acid I
, O
respectively O
, O
both O
of O
which O
had O
lost O
the O
fluorine B
atom O
present O
in O
the O
parent O
compound O
. O

Metabolites O
M2 O
and O
M5 O
were O
the O
alcohol B
and O
carboxylic B
acid I
species O
3 B
- I
hydroxypropyl I
- I
phosphinic I
acid I
and O
3 B
- I
hydroxyphosphonoyl I
- I
propanoic I
acid I
, O
respectively O
, O
both O
of O
which O
had O
lost O
the O
fluorine B
atom O
present O
in O
the O
parent O
compound O
. O

Bis B
( I
12 I
) I
- I
hupyridone I
, O
a O
novel O
acetylcholinesterase O
inhibitor O
, O
protects O
against O
glutamate B
- O
induced O
neuronal O
excitotoxicity O
via O
activating O
alpha O
7 O
nicotinic O
acetylcholine B
receptor O
/ O
phosphoinositide B
3 O
- O
kinase O
/ O
Akt O
cascade O
. O

Bis B
( I
12 I
) I
- I
hupyridone I
( O
B12H B
) O
, O
derived O
from O
the O
Chinese O
medicinal O
component O
huperzine B
A I
, O
was O
originally O
designed O
as O
a O
novel O
acetylcholinesterase O
( O
AChE O
) O
inhibitor O
. O

The O
objective O
of O
this O
review O
is O
to O
summarize O
fundamentals O
, O
applications O
, O
and O
recent O
advances O
of O
injectable O
thermosensitive O
hydrogel O
as O
DDSs O
, O
including O
chitosan O
and O
related O
derivatives O
, O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- O
based O
( O
PNIPAAM B
) O
copolymers O
, O
poly B
( I
ethylene I
oxide I
) I
/ O
poly B
( I
propylene I
oxide I
) I
( O
PEO B
/ O
PPO B
) O
copolymers O
and O
its O
derivatives O
, O
and O
poly B
( I
ethylene I
glycol I
) I
/ O
biodegradable O
polyester B
copolymers O
. O

Preorganization O
of O
polypyridyl B
ligands O
ranging O
from O
bidentate O
to O
tetradentate O
by O
bridging O
benzo B
groups O
, O
as O
are O
present O
in O
1 B
, I
10 I
- I
phenanthroline I
( O
phen B
) O
compared O
to O
2 B
, I
2 I
' I
- I
bipyridyl I
( O
bpy B
) O
, O
is O
discussed O
. O

Pharmacokinetic O
study O
of O
Growth B
Hormone I
- I
Releasing I
Peptide I
6 I
( O
GHRP B
- I
6 I
) O
in O
nine O
male O
healthy O
volunteers O
. O

A O
new O
cyclometallated B
iridium I
( I
III I
) I
complex O
with O
the O
2 B
, I
2 I
' I
- I
biquinoline I
N B
- O
donor O
ligand O
has O
been O
synthesized O
and O
characterized O
. O

In O
this O
work O
, O
phytochemical O
investigation O
of O
litchi O
pericarp O
methanol B
extracts O
led O
to O
the O
isolation O
of O
a O
novel O
phenolic B
, O
2 B
- I
( I
2 I
- I
hydroxyl I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
together O
with O
kaempferol B
, O
isolariciresinol B
, O
stigmasterol B
, O
butylated B
hydroxytoluene I
, O
3 B
, I
4 I
- I
dihydroxyl I
benzoate I
, O
methyl B
shikimate I
and O
ethyl B
shikimate I
. O

Antioxidant O
activities O
of O
the O
eight O
compounds O
were O
determined O
by O
a O
DPPH B
radical O
scavenging O
assay O
and O
the O
results O
showed O
that O
2 B
- I
( I
2 I
- I
hydroxy I
- I
5 I
- I
( I
methoxycarbonyl I
) I
phenoxy I
) I
benzoic I
acid I
, O
kaempferol B
, O
isolariciresinol B
, O
butylated B
hydroxytoluene I
and O
3 B
, I
4 I
- I
dihydroxy I
benzoate I
exhibited O
good O
antioxidant O
activities O
. O

The O
most O
abundant O
compounds O
in O
the O
plant O
extract O
and O
infusion O
were O
5 B
- I
O I
- I
caffeoylquinic I
acid I
and O
an O
apigenin B
derivative O
. O

A O
combination O
of O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Huperzine I
A I
improves O
protection O
against O
soman O
toxicity O
compared O
to O
[ B
+ I
] I
- I
Huperzine I
A I
in O
guinea O
pigs O
. O

[ B
- I
] I
- I
Huperzine I
A I
( O
[ B
- I
] I
- I
Hup I
A I
) O
, O
is O
a O
naturally O
occurring O
potent O
reversible O
AChE O
inhibitor O
that O
penetrates O
the O
blood O
- O
brain O
barrier O
. O

[ B
- I
] I
- I
Huperzine I
A I
( O
[ B
- I
] I
- I
Hup I
A I
) O
, O
is O
a O
naturally O
occurring O
potent O
reversible O
AChE O
inhibitor O
that O
penetrates O
the O
blood O
- O
brain O
barrier O
. O

Toxicities O
at O
higher O
doses O
restrict O
the O
neuroporotective O
ability O
of O
[ B
- I
] I
- I
Hup I
A I
for O
treatment O
. O

The O
synthetic O
stereoisomer O
, O
[ B
+ I
] I
- I
Hup I
A I
, O
is O
less O
toxic O
due O
to O
poor O
AChE O
inhibition O
and O
is O
suitable O
for O
both O
pre O
- O
/ O
post O
- O
exposure O
treatments O
of O
nerve O
agent O
toxicity O
. O

[ B
+ I
] I
- I
Hup I
A I
block O
the O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA B
) O
- O
induced O
seizure O
in O
rats O
, O
reduce O
excitatory O
amino B
acid I
induced O
neurotoxicity O
and O
also O
prevent O
soman O
induced O
toxicity O
with O
minimum O
performance O
decrement O
. O

We O
investigated O
a O
combination O
of O
[ B
+ I
] I
- I
Hup I
A I
with O
a O
small O
dose O
of O
[ B
- I
] I
- I
Hup I
A I
( O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
) O
against O
soman B
toxicity O
. O

We O
investigated O
a O
combination O
of O
[ B
+ I
] I
- I
Hup I
A I
with O
a O
small O
dose O
of O
[ B
- I
] I
- I
Hup I
A I
( O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
) O
against O
soman B
toxicity O
. O

Our O
data O
showed O
that O
pretreatment O
with O
a O
combination O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
significantly O
increased O
the O
survival O
rate O
and O
reduced O
behavioral O
abnormalities O
after O
exposure O
to O
1 O
. O
2 O
x O
LD50 O
soman O
compared O
to O
[ B
+ I
] I
- I
Hup I
A I
in O
guinea O
pigs O
. O

In O
addition O
, O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
pretreatment O
inhibited O
the O
development O
of O
high O
power O
of O
EEG O
better O
than O
[ B
+ I
] I
- I
Hup I
A I
pretreatment O
alone O
. O

These O
data O
suggest O
that O
a O
combination O
of O
[ B
+ I
] I
and I
[ I
- I
] I
- I
Hup I
A I
offers O
better O
protection O
than O
[ B
+ I
] I
- I
Hup I
A I
and O
serves O
as O
a O
potent O
medical O
countermeasure O
against O
lethal O
dose O
nerve O
agent O
toxicity O
in O
guinea O
pigs O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
synthesize O
Pluronic B
F127 I
- I
polyethylenimine I
- I
folate I
( O
PF127 B
- I
PEI I
- I
FA I
) O
copolymer O
, O
construct O
a O
mixed O
micelle O
system O
with O
PF127 B
- I
PEI I
- I
FA I
copolymer O
and O
Pluronic B
P123 I
( O
PP123 B
) O
and O
to O
evaluate O
the O
potential O
of O
these O
mixed O
micelles O
as O
an O
oral O
drug O
delivery O
system O
for O
paclitaxel B
( O
PTX B
) O
. O

Crayfish O
were O
exposed O
to O
1 O
mg O
l O
( O
- O
1 O
) O
( B
14 I
) I
C I
- I
ethion I
and O
the O
concentrations O
of O
ethion B
and O
its O
possible O
degradation O
products O
were O
measured O
in O
water O
and O
different O
organs O
of O
the O
crayfish O
over O
both O
the O
exposure O
and O
recovery O
periods O
. O

Chromatographic O
analysis O
revealed O
that O
ethion B
was O
degraded O
into O
ethion B
monooxon I
, O
ethion B
dioxon I
, O
O B
, I
O I
- I
diethyl I
phosphorothioate I
, O
O B
- I
ethyl I
phosphorothioate I
and O
one O
unknown O
compound O
. O

In O
animal O
studies O
, O
a O
sustained O
release O
rate O
was O
achieved O
with O
both O
PEGylated B
and I
non I
- I
PEGylated I
octreotide I
, O
but O
longer O
delivery O
was O
observed O
for O
PEGylated B
octreotide I
. O

The O
structure O
of O
Delta B
( I
6 I
) I
- I
flunisolide I
was O
unambiguously O
established O
by O
NMR O
analysis O
. O

Structural O
optimization O
of O
2 B
, I
5 I
- I
thiophene I
amides I
as O
highly O
potent O
and O
selective O
17 B
beta I
- I
hydroxysteroid I
dehydrogenase O
type O
2 O
inhibitors O
for O
the O
treatment O
of O
osteoporosis O
. O

We O
report O
here O
the O
optimization O
of O
human O
17 O
beta O
- O
HSD2 O
inhibitors O
in O
the O
2 B
, I
5 I
- I
thiophene I
amide I
class O
by O
varying O
the O
size O
of O
the O
linker O
( O
n O
equals O
0 O
and O
2 O
) O
between O
the O
amide B
moiety O
and O
the O
phenyl B
group O
. O

During O
and O
after O
exposure O
of O
the O
rats O
to O
( B
13 I
) I
C I
- I
FA I
their O
blood O
was O
analyzed O
to O
determine O
the O
ratio O
between O
labeled O
and O
natural O
FA O
in O
blood O
and O
the O
total O
blood O
concentration O
of O
FA O
. O

With O
respect O
to O
sensitivity O
, O
with O
the O
applied O
method O
exogenous O
( B
13 I
) I
C I
- I
FA I
could O
have O
been O
detected O
in O
blood O
at O
a O
concentration O
approximately O
1 O
. O
5 O
% O
of O
the O
endogenous O
FA O
blood O
concentration O
. O

Exogenous O
( B
13 I
) I
C I
- I
FA I
was O
not O
detectable O
in O
the O
blood O
of O
rats O
either O
during O
or O
up O
to O
30 O
min O
after O
the O
exposure O
. O

It O
was O
concluded O
that O
the O
inhalation O
of O
( B
13 I
) I
C I
- I
FA I
at O
10 O
ppm O
for O
6h O
did O
not O
result O
in O
an O
increase O
of O
the O
total O
FA O
concentration O
in O
blood O
. O

In O
most O
catchments O
, O
HCO B
3 I
( I
- I
) I
and O
SO B
4 I
( I
2 I
- I
) I
concentrations O
were O
greater O
than O
Cl B
( I
- I
) I
concentration O
. O

The O
high O
- O
frequency O
reorientation O
dynamics O
of O
O B
- I
( I
2 I
) I
H I
bonds O
is O
investigated O
in O
various O
amorphous O
ices O
including O
eHDA O
( O
expanded O
high O
density O
amorphous O
ice O
) O
, O
LDA O
- O
II O
( O
low O
density O
amorphous O
ice O
II O
) O
and O
HGW O
( O
hyperquenched O
glassy O
water O
) O
using O
( B
2 I
) I
H I
- O
NMR O
spin O
- O
lattice O
relaxation O
as O
a O
local O
probe O
. O

The O
cucurbitacins B
E I
, I
D I
and I
I I
: O
investigation O
of O
their O
cytotoxicity O
toward O
human O
chondrosarcoma O
SW O
1353 O
cell O
line O
and O
their O
biotransformation O
in O
man O
liver O
. O

The O
purpose O
of O
this O
work O
was O
to O
compare O
the O
cytotoxicity O
of O
three O
cucurbitacins B
I I
, I
D I
, I
E I
on O
the O
chondrosarcoma O
SW O
1353 O
cancer O
cell O
line O
and O
to O
investigate O
their O
biotransformation O
in O
man O
. O

This O
study O
shows O
that O
cucurbitacins B
I I
, I
D I
and I
E I
present O
a O
potent O
cytotoxic O
activity O
toward O
the O
chondrosarcoma O
SW O
1353 O
cell O
line O
and O
are O
metabolized O
as O
sulfate B
and O
glucuronide B
conjugates O
. O

4 O
. O
The O
results O
indicated O
that O
M1 O
and O
M2 O
with O
parent O
compound O
( O
M0 O
) O
were O
mainly O
eliminated O
in O
faeces O
and O
three O
glucuronide B
metabolites O
( O
M3 O
, O
M4 O
and O
M5 O
) O
excreted O
in O
bile O
as O
the O
predominant O
forms O
after O
oral O
administration O
of O
GA B
( I
15 I
: I
1 I
) I
to O
rats O
. O

The O
accuracy O
of O
DNA O
synthesis O
depends O
on O
the O
accuracy O
of O
the O
polymerase O
as O
well O
as O
the O
quality O
and O
concentration O
( O
s O
) O
of O
the O
available O
5 B
' I
- I
deoxynucleoside I
- I
triphosphate I
DNA O
precursors O
( O
dNTPs B
) O
. O

Based O
on O
the O
presence O
of O
the O
2 B
, I
2 I
' I
- I
biphenol I
core O
, O
we O
further O
studied O
whether O
achyrofuran B
killed O
bacteria O
through O
a O
mechanism O
of O
action O
similar O
to O
that O
reported O
for O
the O
naturally O
occurring O
antibiotic O
MC21 B
- I
A I
. O

Hexylsubstituted B
poly I
( I
lactic I
acid I
) I
( O
hexPLA B
) O
is O
a O
viscous O
polymer O
, O
which O
degrades O
in O
the O
presence O
of O
water O
similar O
to O
the O
structure O
related O
poly B
( I
lactic I
acid I
) I
. O

Nine O
mycotoxins O
including O
six O
aspergillic B
acid I
group O
toxins O
, O
aluminiumneoaspergil B
( O
1 O
) O
, O
zirconiumneoaspergil B
( O
2 O
) O
, O
aspergilliamide B
( O
3 O
) O
, O
ferrineoaspergillin B
( O
5 O
) O
, O
flavacol B
( O
6 O
) O
, O
neoaspergillic B
acid I
( O
7 O
) O
, O
and O
three O
ochratoxins B
, O
ochratoxin B
A I
n I
- I
butyl I
ester I
( O
4 O
) O
, O
ochratoxin B
A I
( O
8 O
) O
, O
ochratoxin B
A I
methyl I
ester I
( O
9 O
) O
, O
were O
isolated O
from O

One O
new O
monoterpenoid B
, O
( B
+ I
) I
- I
argutoid I
A I
( O
1 O
) O
, O
three O
new O
iridoids B
, O
( B
- I
) I
- I
incarvoid I
A I
( O
2 O
) O
, O
( B
+ I
) I
- I
incarvoid I
B I
( O
3 O
) O
, O
and O
incarvoid B
C I
( O
4 O
) O
, O
and O
five O
known O
compounds O
were O
isolated O
from O
Incarvillea O
arguta O
. O

One O
new O
monoterpenoid B
, O
( B
+ I
) I
- I
argutoid I
A I
( O
1 O
) O
, O
three O
new O
iridoids B
, O
( B
- I
) I
- I
incarvoid I
A I
( O
2 O
) O
, O
( B
+ I
) I
- I
incarvoid I
B I
( O
3 O
) O
, O
and O
incarvoid B
C I
( O
4 O
) O
, O
and O
five O
known O
compounds O
were O
isolated O
from O
Incarvillea O
arguta O
. O

One O
new O
monoterpenoid B
, O
( B
+ I
) I
- I
argutoid I
A I
( O
1 O
) O
, O
three O
new O
iridoids B
, O
( B
- I
) I
- I
incarvoid I
A I
( O
2 O
) O
, O
( B
+ I
) I
- I
incarvoid I
B I
( O
3 O
) O
, O
and O
incarvoid B
C I
( O
4 O
) O
, O
and O
five O
known O
compounds O
were O
isolated O
from O
Incarvillea O
arguta O
. O

Amino B
acid I
- O
based O
zwitterionic B
poly I
( I
serine I
methacrylate I
) I
as O
an O
antifouling O
material O
. O

A O
serine B
- O
based O
zwitterionic B
poly I
( I
serine I
methacrylate I
) I
( O
pSerMA B
) O
was O
developed O
in O
this O
work O
to O
be O
used O
as O
a O
potential O
antifouling O
material O
. O

The O
microcapsules O
were O
subsequently O
placed O
within O
a O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
- O
coated O
poly B
( I
epsilon I
- I
caprolactone I
) I
( O
PCL B
) O
chamber O
covered O
with O
a O
PEG B
- I
grafted I
PCL I
nanoporous O
membrane O
formed O
by O
phase O
inversion O
. O

Moreover O
, O
VK2 B
- I
2 I
, I
3 I
epoxide I
, O
an O
intracellular O
metabolite O
of O
VK2 B
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine B
- O
166 O
residue O
of O
Bak O
. O

Relative O
oral O
bioavailability O
of O
3 B
- I
MCPD I
from O
3 B
- I
MCPD I
fatty I
acid I
esters I
in O
rats O
. O

In O
order O
to O
quantify O
the O
relative O
oral O
bioavailability O
of O
3 B
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
) O
from O
3 B
- I
MCPD I
fatty I
acid I
diesters I
in O
vivo O
, O
1 B
, I
2 I
- I
dipalmitoyl I
- I
3 I
- I
chloropropane I
- I
1 I
, I
2 I
- I
diol I
( O
3 B
- I
MCPD I
diester I
) O
and O
3 B
- I
MCPD I
were O
orally O
applied O
to O
rats O
in O
equimolar O
doses O
. O

Although O
not O
the O
most O
active O
, O
4 B
- I
NH I
( I
2 I
) I
substituted O
compounds O
possessed O
the O
lowest O
in O
vitro O
cytotoxicity O
( O
hepatotoxicity O
) O
, O
leading O
to O
selectivity O
index O
SI O
= O
5 O
. O
5 O
and O
SI O
> O
21 O
. O

These O
drug O
mechanism O
of O
action O
studies O
demonstrate O
that O
UCD38B B
induces O
a O
cell O
cycle O
- O
independent O
, O
caspase O
- O
independent O
necroptotic O
glioma O
cell O
death O
that O
is O
mediated O
by O
AIF O
and O
independent O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
and O
H2AX O
activation O
. O

In O
ES O
- O
2 O
and O
SKOV3 O
xenograft O
models O
, O
3 O
- O
drug O
PEG B
- I
b I
- I
PCL I
micelles O
had O
significantly O
less O
tumor O
burden O
than O
paclitaxel B
based O
on O
bioluminescence O
imaging O
, O
3 B
' I
- I
deoxy I
- I
3 I
' I
- I
( I
18 I
) I
F I
- I
fluorothymidine I
( O
( B
18 I
) I
F I
- I
FLT I
) O
PET O
imaging O
, O
and O
overall O
survival O
. O

( B
18 I
) I
F I
- I
FLT I
- O
PET O
images O
clearly O
showed O
that O
3 O
- O
drug O
PEG B
- I
b I
- I
PCL I
micelles O
dramatically O
reduce O
tumor O
volumes O
over O
paclitaxel B
and O
vehicle O
controls O
. O

While O
the O
large O
size O
of O
the O
4 B
, I
4 I
- I
benzenebiphenyldicar I
acid I
( O
BDPC B
) O
ligand O
has O
a O
positive O
impact O
on O
the O
adsorption O
of O
NO B
( I
2 I
) I
on O
UiO B
- I
67 I
in O
moist O
conditions O
, O
the O
opposite O
effect O
is O
found O
in O
dry O
conditions O
. O

We O
report O
the O
IR O
spectra O
of O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
( I
+ I
) I
, O
1 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
, O
and O
2 B
- I
C I
( I
10 I
) I
H I
( I
9 I
) I
trapped O
in O
solid O
para B
- I
hydrogen I
( O
p B
- I
H I
( I
2 I
) I
) O
; O
the O
latter O
three O
are O
new O
. O

These O
species O
were O
produced O
upon O
electron O
bombardment O
of O
a O
mixture O
of O
naphthalene B
( O
C B
( I
10 I
) I
H I
( I
8 I
) I
) O
and O
p B
- I
H I
( I
2 I
) I
during O
matrix O
deposition O
. O

On O
the O
basis O
of O
the O
isolated O
compounds O
, O
a O
presumable O
biogenetic O
pathway O
of O
the O
biologically O
interesting O
phenylethanoid B
glycosides I
about O
forsythoside B
B I
( O
3 O
) O
and O
acteoside B
( O
4 O
) O
isolated O
from O
this O
species O
was O
proposed O
. O

Synthesis O
of O
new O
N B
- I
( I
arylcyclopropyl I
) I
acetamides I
and O
N B
- I
( I
arylvinyl I
) I
acetamides I
as O
conformationally O
- O
restricted O
ligands O
for O
melatonin B
receptors O
. O

Synthesis O
of O
new O
N B
- I
( I
arylcyclopropyl I
) I
acetamides I
and O
N B
- I
( I
arylvinyl I
) I
acetamides I
as O
conformationally O
- O
restricted O
ligands O
for O
melatonin B
receptors O
. O

N B
- I
( I
Arylcyclopropyl I
) I
acetamides I
and O
N B
- I
( I
arylvinyl I
) I
acetamides I
or O
methyl B
ureas I
have O
been O
prepared O
as O
constrained O
analogues O
of O
melatonin B
. O

N B
- I
( I
Arylcyclopropyl I
) I
acetamides I
and O
N B
- I
( I
arylvinyl I
) I
acetamides I
or O
methyl B
ureas I
have O
been O
prepared O
as O
constrained O
analogues O
of O
melatonin B
. O

The O
2 B
, I
5 I
- I
disubstituted I
oxazole I
recently O
proposed O
for O
aspongopusin B
, O
a O
natural O
product O
isolated O
from O
Aspongopus O
chinensis O
, O
was O
synthesized O
through O
an O
unambiguous O
route O
. O

We O
assessed O
OH B
production O
by O
quantifying O
the O
rate O
of O
formation O
of O
3 B
, I
4 I
- I
dihydroxybenzoic I
acid I
using O
a O
trapping O
agent O
, O
4 B
- I
hydroxybenzoic I
acid I
, O
infused O
via O
the O
microdialysis O
probe O
, O
into O
the O
prefrontal O
cortex O
of O
rats O
exposed O
intraperitoneally O
to O
the O
solvents O
. O

Their O
Fe B
( I
III I
/ I
II I
) I
redox O
potentials O
were O
all O
within O
the O
range O
accessible O
to O
cellular O
oxidants O
and O
reductants O
, O
suggesting O
they O
can O
redox O
cycle O
. O

Disposition O
of O
tacrolimus B
and O
its O
major O
metabolites O
, O
13 B
- I
O I
- I
desmethyl I
tacrolimus I
and O
15 B
- I
O I
- I
desmethyl I
tacrolimus I
, O
was O
evaluated O
in O
stable O
kidney O
transplant O
recipients O
in O
relation O
to O
diabetes O
mellitus O
and O
genetic O
polymorphism O
of O
cytochrome O
P450 O
( O
CYP O
) O
3A O
. O

Disposition O
of O
tacrolimus B
and O
its O
major O
metabolites O
, O
13 B
- I
O I
- I
desmethyl I
tacrolimus I
and O
15 B
- I
O I
- I
desmethyl I
tacrolimus I
, O
was O
evaluated O
in O
stable O
kidney O
transplant O
recipients O
in O
relation O
to O
diabetes O
mellitus O
and O
genetic O
polymorphism O
of O
cytochrome O
P450 O
( O
CYP O
) O
3A O
. O

Coatline B
A I
( O
1 O
) O
and O
alpha B
- I
epi I
- I
coatline I
A I
( O
4 O
) O
co O
- O
occur O
in O
the O
trunk O
extract O
of O
Andira O
coriacea O
. O

Our O
results O
suggest O
that O
1 B
, I
8 I
- I
naphthalimide I
derivatives O
with O
electron O
- O
donating O
- B
OCH3 I
and O
- B
N I
( I
CH3 I
) I
2 I
( O
1 O
and O
2 O
) O
, O
electron O
- O
withdrawing O
- B
CN I
and O
- B
COCH3 I
( O
3 O
and O
4 O
) O
, O
2 B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
thiophene I
( O
5 O
) O
, O
2 B
, I
3 I
- I
dihydrothieno I
[ I
3 I
, I
4 I
- I
b I
] I
[ I
1 I
, I
4 I
] I
dioxine I
( O
6 O
) O
, O
2 B
- I
phenyl I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
7 O
) O
, O
and O

To O
obtain O
further O
insight O
into O
the O
functional O
significance O
of O
the O
covalent O
bond O
between O
Cys707 B
and O
the O
coenzyme O
, O
and O
the O
overall O
role O
of O
the O
two O
catalytic O
residues O
in O
the O
coenzyme O
binding O
and O
positioning O
, O
we O
have O
now O
solved O
crystal O
structures O
of O
Ct O
- O
FDH O
in O
the O
complex O
with O
thio B
- I
NADP I
( I
+ I
) I
and O
the O
complexes O
of O
the O
C707S O
mutant O
with O
NADP B
( I
+ I
) I
and O
NADPH B
. O

The O
insertion O
of O
aptamer O
sequences O
( O
e O
. O
g O
. O
, O
the O
adenosine B
- I
5 I
' I
- I
triphosphate I
( O
ATP B
) O
aptamer O
) O
or O
ion O
- O
binding O
sequences O
( O
e O
. O
g O
. O
, O
T O
- O
rich O
Hg B
( I
2 I
+ I
) I
ion O
- O
binding O
domains O
) O
as O
foreign O
components O
to O
the O
loop O
regions O
allows O
the O
formation O
of O
active O
Mg B
( I
2 I
+ I
) I
- O
or O
Zn B
( I
2 I
+ I
) I
- O
dependent O
DNAzyme O
structures O
through O
the O
cooperative O
formation O
of O
aptamer O
- O
ATP B
complexes O
or O
T O
- O
Hg B
( I
2 I
+ I
) I
- O
T O
bridges O
. O

As O
carbaboranes B
represent O
interesting O
pharmacophores O
as O
phenyl B
mimetics O
in O
drug O
development O
, O
this O
paper O
presents O
the O
synthesis O
of O
carbaboranyl B
derivatives O
of O
COX O
- O
2 O
- O
selective O
2 B
, I
3 I
- I
disubstituted I
indoles I
. O

Unidirectional O
PhIP B
flux O
rates O
from O
the O
mucosal O
- O
to O
- O
the O
serosal O
compartment O
( O
J O
ms O
) O
and O
in O
the O
opposite O
direction O
( O
J O
sm O
) O
were O
examined O
in O
Ussing O
chambers O
with O
( B
14 I
) I
C I
- I
PhIP I
as O
radiotracer O
and O
in O
the O
absence O
of O
electrochemical O
gradients O
. O

( B
+ I
) I
- I
Usnic I
acid I
( O
green O
) O
is O
a O
weak O
antimalarial O
agent O
, O
however O
, O
in O
conjugation O
with O
known O
antimalarial O
scaffolds O
and O
drugs O
, O
such O
as O
dihydroartemisinin B
( O
blue O
) O
, O
potent O
activity O
against O
the O
blood O
- O
stage O
parasite O
can O
be O
seen O
both O
in O
vitro O
and O
in O
vivo O
. O

Objective O
: O
The O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
the O
effects O
of O
melatonin B
on O
biochemical O
and O
cardiovascular O
changes O
resulting O
from O
exposure O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
a O
polychlorinated B
dibenzo I
- I
para I
- I
dioxin I
. O
Methods O
: O
A O
total O
of O
24 O
Sprague O
- O
Dawley O
rats O
were O
divided O
equally O
into O
the O
following O
four O
groups O
: O
( O
1 O
) O
control O
group O
was O
administered O
with O
0 O
. O
5 O
mL O
corn O
oil O
by O
gavage O
and O
0 O
. O
5 O
cc O
vehicle O
of O

Thio O
derivatives O
of O
hydroxytyrosol B
containing O
thiol B
, O
thioacetate B
and O
disulfide B
functionalities O
were O
synthesized O
from O
natural O
hydroxytyrosol B
( O
3 B
, I
4 I
- I
DHPEA I
) O
via O
3 B
, I
4 I
- I
dihydroxyphenethyl I
halides I
. O

Histidine B
dipeptides O
such O
as O
carnosine B
form O
Michael O
adducts O
with O
lipid O
- O
derived O
unsaturated B
aldehydes I
, O
and O
react O
with O
carbohydrate B
- O
derived O
oxo B
- I
and I
hydroxy I
- I
aldehydes I
forming O
products O
of O
unknown O
structure O
. O

By O
means O
of O
HPLC O
- O
DAD O
- O
ESI O
- O
MS O
, O
the O
main O
flavonoids B
in O
D O
. O
boryanum O
were O
tentatively O
identified O
as O
3 B
- I
hydroxyphloretin I
6 I
' I
- I
O I
- I
hexoside I
, O
quercetin B
- I
7 I
- I
hexoside I
, O
apigenin7 B
- I
O I
- I
glucoside I
, O
luteolin B
7 I
- I
O I
- I
glucoside I
, O
apigenin B
7 I
- I
O I
- I
galactoside I
, O
acacetin B
7 I
- I
O I
- I
( I
alpha I
- I
D I
- I
apio I
- I
furanosyl I
) I
( I
1 I
- I
- I
> I
6 I

By O
means O
of O
HPLC O
- O
DAD O
- O
ESI O
- O
MS O
, O
the O
main O
flavonoids B
in O
D O
. O
boryanum O
were O
tentatively O
identified O
as O
3 B
- I
hydroxyphloretin I
6 I
' I
- I
O I
- I
hexoside I
, O
quercetin B
- I
7 I
- I
hexoside I
, O
apigenin7 B
- I
O I
- I
glucoside I
, O
luteolin B
7 I
- I
O I
- I
glucoside I
, O
apigenin B
7 I
- I
O I
- I
galactoside I
, O
acacetin B
7 I
- I
O I
- I
( I
alpha I
- I
D I
- I
apio I
- I
furanosyl I
) I
( I
1 I
- I
- I
> I
6 I

The O
present O
studies O
examined O
a O
selected O
series O
of O
para B
- I
phenyl I
- I
substituted I
diindolylmethane I
( O
C O
- O
DIM O
) O
compounds O
that O
display O
anti O
- O
inflammatory O
and O
neuroprotective O
efficacy O
in O
vitro O
. O

None O
of O
the O
metabolites O
cotinine B
, O
cotinine B
- I
N I
- I
oxide I
, O
nicotine B
- I
1 I
' I
- I
N I
- I
oxide I
or O
trans B
- I
3 I
' I
- I
hydroxycotinine I
( O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
affected O
platelet O
aggregation O
or O
P O
- O
selectin O
expression O
. O

Nicotine B
( O
10 O
mu O
M O
) O
weakly O
increased O
platelet O
aggregation O
, O
whereas O
trans B
- I
3 I
' I
- I
hydroxycotinine I
( O
0 O
. O
1 O
mu O
M O
) O
and O
nicotine B
- I
1 I
' I
- I
N I
- I
oxide I
( O
1 O
- O
10 O
mu O
M O
) O
weakly O
inhibited O
adhesion O
to O
fibrinogen O
. O

A O
new O
di B
- I
O I
- I
prenylated I
flavone I
from O
an O
actinomycete O
Streptomyces O
sp O
. O

A O
new O
di B
- I
O I
- I
prenylated I
flavone I
, O
named O
7 B
, I
3 I
' I
- I
di I
- I
( I
gamma I
, I
gamma I
- I
dimethylallyloxy I
) I
- I
5 I
- I
hydroxy I
- I
4 I
' I
- I
methoxyflavone I
( O
1 O
) O
, O
was O
isolated O
from O
the O
culture O
broth O
of O
the O
endophytic O
actinomycete O
Streptomyces O
sp O
. O

Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin B
3 I
- I
O I
- I
gallate I
and O
several O
quercetin B
derivatives O
. O

Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin B
3 I
- I
O I
- I
gallate I
( O
EGCG B
) O
and O
most O
of O
compounds O
1 O
- O
6 O
killed O
preferentially O
OATP O
- O
expressing O
CHO O
cells O
. O

Liquified O
capsules O
featuring O
( O
i O
) O
an O
external O
shell O
by O
layer O
- O
by O
- O
layer O
assembly O
of O
poly B
( I
l I
- I
lysine I
) I
, O
alginate O
, O
and O
chitosan O
, O
and O
encapsulating O
( O
ii O
) O
surface O
functionalized O
poly B
( I
l I
- I
lactic I
acid I
) I
( O
PLLA B
) O
microparticles O
were O
developed O
. O

Interaction O
between O
group B
IIb I
divalent I
transition I
- I
metal I
cations O
and O
3 B
- I
mercaptopropionic I
acid I
: O
a O
computational O
and O
topological O
perspective O
. O

Comparative O
toxicological O
study O
of O
the O
novel O
protein O
phosphatase O
inhibitor O
19 B
- I
Epi I
- I
okadaic I
acid I
in O
primary O
cultures O
of O
rat O
cerebellar O
cells O
. O

Herein O
, O
we O
highlight O
for O
the O
first O
time O
a O
universal O
in O
- O
plane O
coassembly O
process O
for O
the O
design O
and O
synthesis O
of O
transition B
- I
metal I
chalcogenide I
- I
alkylamine I
inorganic O
- O
organic O
hybrid O
nanosheets O
with O
atomic O
thickness O
. O

Mass O
spectrometry O
method O
to O
identify O
aging O
pathways O
of O
Sp B
- I
and I
Rp I
- I
tabun I
adducts O
on O
human O
butyrylcholinesteras O
based O
on O
the O
acid O
labile O
P B
- I
N I
bond O
. O

Up O
to O
19 O
simple O
polyphenols B
were O
determined O
in O
mushrooms O
extracts O
, O
the O
more O
abundant O
being O
p B
- I
OH I
- I
benzoic I
acid I
, O
p B
- I
OH I
- I
phenylacetic I
acid I
, O
o B
- I
coumaric I
acid I
, O
ferulic B
acid I
and O
chrysin B
. O

Up O
to O
19 O
simple O
polyphenols B
were O
determined O
in O
mushrooms O
extracts O
, O
the O
more O
abundant O
being O
p B
- I
OH I
- I
benzoic I
acid I
, O
p B
- I
OH I
- I
phenylacetic I
acid I
, O
o B
- I
coumaric I
acid I
, O
ferulic B
acid I
and O
chrysin B
. O

Dichloro B
- I
dihydro I
- I
fluorescein I
diacetate I
( O
DCFH B
- I
DA I
) O
assay O
: O
a O
quantitative O
method O
for O
oxidative O
stress O
assessment O
of O
nanoparticle O
- O
treated O
cells O
. O

No O
consensus O
exists O
on O
how O
to O
address O
possible O
toxicity O
of O
nanomaterials O
as O
they O
interfere O
with O
most O
in O
vitro O
screening O
tests O
based O
on O
colorimetric O
and O
fluorimetric O
probes O
such O
as O
the O
dichloro B
- I
dihydro I
- I
fluorescein I
diacetate I
( O
DCFH B
- I
DA I
) O
assay O
for O
detection O
of O
oxidative O
species O
. O

Sialylneolacto B
- I
N I
- I
tetraose I
c I
( O
LSTc B
) O
- O
bearing O
liposomal O
decoys O
capture O
influenza O
A O
virus O
. O

We O
used O
liposomes O
as O
a O
novel O
means O
for O
delivery O
of O
the O
glycan O
sialylneolacto B
- I
N I
- I
tetraose I
c I
( O
LSTc B
) O
. O

Electrochemiluminesc O
biosensor O
based O
on O
conducting O
poly B
( I
5 I
- I
formylindole I
) I
for O
sensitive O
detection O
of O
Ramos O
cells O
. O

A O
signal O
- O
on O
electrochemiluminesc O
( O
ECL O
) O
biosensor O
devoted O
to O
the O
detection O
of O
Ramos O
cells O
was O
fabricated O
based O
on O
a O
novel O
conducting O
polymer O
, O
poly B
( I
5 I
- I
formylindole I
) I
( O
P5FIn B
) O
, O
which O
was O
synthesized O
electrochemically O
by O
direct O
anodic O
oxidation O
of O
5 B
- I
formylindole I
( O
5FIn B
) O
. O

The O
mass O
of O
the O
heavy O
perdeuterated O
form O
is O
~ O
5 O
. O
5 O
% O
greater O
than O
that O
of O
the O
protiated O
form O
, O
causing O
kinetic O
isotope O
effects O
( O
KIEs O
) O
of O
~ O
1 O
. O
3 O
on O
k O
( O
cat O
) O
and O
k O
( O
cat O
) O
/ O
K O
( O
M O
) O
for O
both O
L B
- I
and I
D I
- I
alanine I
. O

For O
this O
purpose O
, O
markers O
of O
bone O
formation O
( O
osteocalcin O
, O
procollagen O
I O
, O
osteoprotegerin O
, O
alkaline O
phosphatase O
) O
and O
resorption O
( O
telopeptides O
of O
collagen O
I O
, O
soluble O
receptor O
activator O
of O
nuclear O
factor O
- O
kappa O
B O
ligand O
) O
, O
calciotropic O
hormones O
( O
parathormone O
, O
calcitonin O
, O
25 B
- I
hydroxyvitamin I
D I
and O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
) O
in O
the O
serum O
, O
and O
the O
femur O
content O
of O
mineral O
( O
including O
calcium B
- O

Isolation O
of O
a O
flavonoid B
, O
apigenin B
7 I
- I
O I
- I
glucoside I
, O
from O
Mentha O
longifolia O
( O
L O
. O
) O
Hudson O
subspecies O
longifolia O
and O
its O
genotoxic O
potency O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
mutagenic O
and O
antimutagenic O
activities O
of O
apigenin B
7 I
- I
O I
- I
glucoside I
( O
A7G B
) O
, O
a O
flavonoid B
isolated O
from O
Mentha O
longifolia O
( O
L O
. O
) O
Hudson O
subspecies O
longifolia O
( O
ML O
) O
. O

The O
mixed O
- O
valence O
diiron B
hydrido B
complex O
( B
mu I
- I
H I
) I
Fe2 I
( I
pdt I
) I
( I
CO I
) I
2 I
( I
dppv I
) I
2 I
( O
[ O
H1 B
] O
( O
0 O
) O
, O
where O
pdt B
= O
1 B
, I
3 I
- I
propanedithiolate I
and O
dppv B
= O
cis B
- I
1 I
, I
2 I
- I
C2H2 I
( I
PPh2 I
) I
2 I
) O
, O
was O
generated O
by O
reduction O
of O
the O
differous O
hydride B
[ B
H1 I
] I
( I
+ I
) I
using O
decamethylcobaltocen B
. O

The O
EPR O
spectra O
of O
[ O
H1 B
] O
( O
0 O
) O
and O
[ O
D1 O
] O
( O
0 O
) O
demonstrate O
that O
the O
singly O
occupied O
molecular O
orbital O
is O
primarily O
localized O
on O
the O
Fe B
center O
with O
the O
longer O
bond O
to O
H B
, O
that O
is O
, O
Fe B
( I
II I
) I
- I
H I
. O
. O
. O
Fe B
( I
I I
) I
. O

Treatment O
of O
[ O
H1 B
] O
( O
0 O
) O
with O
H B
( I
+ I
) I
gives O
0 O
. O
5 O
equiv O
of O
H2 B
and O
[ B
H1 I
] I
( I
+ I
) I
. O

Unlike O
CsoR O
, O
CstR O
does O
not O
form O
a O
stable O
complex O
with O
transition B
metals I
but O
instead O
reacts O
with O
sulfite B
to O
form O
a O
mixture O
of O
di B
- I
and I
trisulfide I
species O
, O
CstR2 O
( O
RS B
- I
SR I
' I
) O
and O
CstR2 O
( O
RS B
- I
S I
- I
SR I
' I
) O
n O
) O
n O
= O
1 O
or O
2 O
, O
respectively O
. O

We O
show O
that O
Cys31 B
initiates O
the O
reaction O
with O
sulfite B
through O
the O
formation O
of O
S B
- I
sulfocysteine I
( O
RS B
- I
SO3 I
( I
2 I
- I
) I
) O
and O
Cys60 B
is O
required O
to O
fully O
derivatize O
CstR O
to O
CstR2 O
( O
RS B
- I
SR I
' I
) O
and O
CstR2 O
( O
RS B
- I
S I
- I
SR I
' I
) O
. O

Mn B
( O
10 O
and O
20 O
mg O
/ O
kg O
) O
increased O
caspase O
activity O
and O
F B
( I
2 I
) I
- I
isoprostane I
production O
( O
a O
biological O
marker O
of O
lipid O
peroxidation O
) O
. O

Notably O
, O
the O
antioxidant O
Trolox B
( O
TM O
) O
reversed O
the O
Mn B
( O
20 O
mg O
/ O
kg O
) O
- O
dependent O
augmentation O
in O
p38 O
( O
MAPK O
) O
phosphorylation O
and O
reduced O
the O
Mn B
( O
20 O
mg O
/ O
kg O
) O
- O
induced O
caspase O
activity O
and O
F B
( I
2 I
) I
- I
isoprostane I
production O
. O

Organothiols B
and O
other O
AuNP O
surface O
adsorbates O
such O
as O
thiophene B
, O
adenine B
, O
rhodamine B
, O
small O
anions O
( O
Br B
( I
- I
) I
and O
I B
( I
- I
) I
) O
, O
and O
a O
polymer O
( O
PVP B
, O
poly B
( I
N I
- I
vinylpyrrolidone I
) I
) O
can O
all O
be O
rapidly O
and O
completely O
removed O
from O
the O
AuNP O
surfaces O
. O

Although O
the O
reaction O
of O
12 B
- I
OH I
- I
NVP I
sulfate I
with O
nucleophiles O
such O
as O
glutathione B
is O
slow O
, O
incubation O
of O
this O
sulfate B
with O
homogenized O
human O
and O
rat O
skin O
led O
to O
extensive O
covalent O
binding O
. O

These O
data O
provide O
strong O
evidence O
that O
covalent O
binding O
of O
NVP B
in O
the O
skin O
is O
due O
to O
12 B
- I
OH I
- I
NVP I
sulfate I
, O
which O
is O
likely O
responsible O
for O
NVP B
- O
induced O
skin O
rash O
. O

( B
- I
) I
- I
Epigallocatechin I
gallate I
, O
cyclosporin B
A I
, O
rifampicin B
, O
and O
telmisartan B
inhibited O
transport O
of O
dioscin B
in O
OATP1B3 O
- O
HEK293 O
cells O
. O

This O
article O
reports O
the O
pK O
( O
a O
) O
shift O
of O
an O
anti O
- O
cancer O
drug O
, O
20 B
( I
S I
) I
- I
camptothecin I
( O
CPT B
) O
, O
upon O
encapsulation O
into O
the O
nanocavity O
of O
a O
cucurbit B
[ I
7 I
] I
uril I
( O
CB7 B
) O
macrocycle O
. O

In O
overexpressing O
cell O
lines O
, O
OATP1B1 O
- O
and O
OATP1B3 O
- O
mediated O
estradiol B
- I
17 I
beta I
- I
glucuronide I
uptake O
and O
OATP2B1 O
- O
mediated O
estrone B
- I
3 I
- I
sulfate I
uptake O
were O
inhibited O
by O
most O
of O
the O
silymarin O
flavonolignans B
investigated O
. O

Furthermore O
, O
silymarin O
, O
silybin B
A I
, O
and O
silybin B
B I
( O
100 O
micro O
M O
) O
significantly O
inhibited O
OATP O
- O
mediated O
estradiol B
- I
17 I
beta I
- I
glucuronide I
and O
rosuvastatin B
uptake O
into O
human O
hepatocytes O
. O

Li B
- I
O I
( I
2 I
) I
battery O
is O
regarded O
as O
one O
of O
the O
most O
promising O
energy O
storage O
systems O
for O
future O
applications O
. O

Here O
, O
a O
K B
- I
O I
( I
2 I
) I
battery O
is O
report O
that O
uses O
K B
( I
+ I
) I
ions O
to O
capture O
O B
( I
2 I
) I
( I
- I
) I
to O
form O
the O
thermodynamically O
stable O
KO B
( I
2 I
) I
product O
. O

The O
adsorption O
of O
the O
model O
perfumes O
phenyl B
ethanol I
, O
PE O
, O
and O
linalool B
, O
LL O
, O
at O
the O
air O
- O
solution O
interface O
by O
coadsorption O
with O
the O
anionic O
surfactant O
sodium B
dodecyl I
6 I
- I
benezene I
sulfonate I
, O
LAS B
- I
6 I
, O
has O
been O
studied O
primarily O
by O
neutron O
reflectivity O
, O
NR O
. O

Histone O
deacetylases O
have O
been O
found O
to O
influence O
cellular O
function O
by O
catalyzing O
the O
removal O
of O
acetyl B
groups O
from O
epsilon B
- I
N I
- I
acetylated I
lysine I
residues O
of O
several O
protein O
substrates O
including O
histones O
, O
transcription O
factors O
, O
alpha O
- O
tubulin O
, O
and O
nuclear O
importers O
. O

In O
contrast O
, O
the O
4 B
, I
4 I
' I
- I
dibromobiphenyl I
monolayer O
is O
observed O
when O
the O
aqueous O
solution O
is O
used O
as O
a O
medium O
to O
carry O
out O
the O
grafting O
experiment O
. O

After O
spiking O
nicotinamide B
- I
d I
( I
4 I
) I
as O
an O
internal O
standard O
, O
infant O
formula O
and O
breakfast O
cereal O
samples O
were O
hydrolysed O
under O
alkaline O
condition O
. O

In O
the O
case O
of O
multivitamin O
sample O
that O
contains O
mainly O
free O
nicotinamide B
, O
LC O
/ O
MS O
monitored O
nicotinamide B
and O
nicotinamide B
- I
d I
( I
4 I
) I
at O
their O
SRM O
channels O
of O
m O
/ O
z O
123 O
- O
- O
> O
80 O
and O
m O
/ O
z O
127 O
- O
- O
> O
84 O
, O
respectively O
, O
after O
simple O
extraction O
. O

Further O
analysis O
revealed O
a O
G0 O
/ O
G1 O
arrest O
of O
the O
phase O
cell O
progression O
and O
apoptosis O
, O
linked O
to O
modulation O
of O
Bax O
, O
Bcl2 O
, O
caspase O
- O
9 O
and O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
as O
well O
as O
Reactive O
Oxygen B
Species O
( O
ROS O
) O
generation O
in O
both O
colon O
cancer O
cells O
, O
whereas O
apoptosis O
and O
ROS O
were O
not O
significantly O
detected O
in O
normal O
human O
lymphocytes O
. O

The O
results O
confirmed O
: O
( O
a O
) O
the O
effectiveness O
of O
single O
process O
indicators O
of O
roasting O
selected O
by O
the O
separative O
method O
( O
5 B
- I
methylfurfural I
, O
1 B
( I
H I
) I
- I
pyrrole I
, O
furfuryl B
alcohol I
, O
1 B
( I
H I
) I
- I
pyrrole I
- I
2 I
- I
carboxaldehyde I
, O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
dihydro B
- I
2 I
( I
3H I
) I
- I
furanone I
, O
5 B
- I
methyl I
- I
( I
E I
) I
- I
2 I
- I
hepten I
- I
4 I
- I
one I
, O
acetic B
acid I
, O
pyridine B
, O
furfural B
, O

Trifluoromethylcyclo B
N I
( I
1 I
) I
triazole I
, O
compound O
51 O
, O
was O
identified O
as O
a O
potent O
and O
selective O
Kv1 O
. O
5 O
inhibitor O
with O
an O
acceptable O
PK O
and O
liability O
profile O
. O

Hollow O
multilayer O
microcapsules O
made O
of O
aliphatic B
poly I
( I
urethane I
- I
amine I
) I
( O
PUA B
) O
and O
sodium B
poly I
( I
styrene I
sulfonate I
) I
( O
PSS B
) O
, O
templated O
on O
PSS B
- O
doped O
CaCO3 B
particles O
, O
are O
prepared O
for O
pH O
- O
/ O
thermally O
responsive O
drug O
delivery O
. O

The O
mechanism O
by O
which O
compound O
1 O
activated O
Nrf2 O
signaling O
was O
supposed O
to O
be O
a O
covalent O
modification O
of O
the O
sulfhydryl B
groups O
of O
Keap1 O
by O
an O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
group O
present O
in O
the O
compound O
1 O
. O

In O
conclusion O
, O
BPA B
has O
adverse O
effects O
on O
phosphorylation O
of O
Akt O
, O
GLUT4 O
translocation O
and O
( B
14 I
) I
C I
- I
glucose I
oxidation O
. O

Novel O
microwave O
assisted O
chemical O
synthesis O
of O
Nd B
2 I
Fe I
1 I
4 I
B I
hard O
magnetic O
nanoparticles O
. O

Here O
, O
we O
show O
that O
N B
, I
N I
- I
diethyl I
- I
N I
- I
methyl I
- I
N I
- I
( I
2 I
- I
methoxyethyl I
) I
ammonium I
tetrafluoroborate I
( O
[ B
DEME I
] I
[ I
BF4 I
] I
) O
could O
be O
crystallized O
upon O
compression O
, O
but O
it O
usually O
formed O
a O
superpressed O
liquid O
. O

These O
facts O
along O
with O
visual O
observations O
indicate O
the O
possibility O
of O
[ B
DEME I
] I
[ I
BF4 I
] I
serving O
as O
a O
superpressurized O
glass O
. O

Here O
we O
demonstrated O
that O
Rad9 O
was O
involved O
in O
nucleotide B
excision O
repair O
and O
loss O
of O
Rad9 O
led O
to O
defective O
removal O
of O
the O
UV O
- O
derived O
photoproduct O
6 B
- I
4PP I
( O
6 B
, I
4 I
pyrimidine I
- I
pyrimidone I
) O
and O
the O
BPDE B
( O
anti O
- O
benzo B
( I
a I
) I
pyrene I
- I
trans I
- I
7 I
, I
8 I
- I
dihydrodiol I
- I
9 I
, I
10 I
- I
epoxide I
) O
- O
DNA O
adducts O
in O
mammalian O
cells O
. O

Synthesis O
and O
evaluation O
of O
the O
naphthylguanide B
compounds O
identified O
our O
best O
compound O
, O
spermine B
tris I
- I
1 I
- I
naphthylguanide I
, O
which O
bound O
CXCR4 O
with O
an O
IC O
( O
50 O
) O
of O
40 O
nM O
and O
inhibited O
the O
infection O
of O
TZM O
- O
bl O
cells O
with O
X4 O
, O
but O
not O
R5 O
, O
strains O
of O
HIV O
- O
1 O
with O
an O
IC O
( O
50 O
) O
of O
50 O
- O
100 O
nM O
. O

The O
convergent O
synthetic O
strategy O
includes O
the O
preparation O
of O
a O
trans B
- I
A2 I
B I
- I
corrole I
possessing O
the O
imide B
unit O
, O
followed O
by O
Sonogashira O
coupling O
with O
a O
meso B
- I
substituted I
A3 I
B I
- I
porphyrin I
. O

Chemical O
modifications O
based O
on O
the O
crystal O
structure O
of O
2 B
- I
( I
phosphonoethoxy I
) I
ethylguanine I
( O
PEEG B
) O
in O
complex O
with O
human O
HGPRT O
have O
led O
to O
the O
design O
of O
new O
ANPs B
. O

GC O
- O
MS O
and O
GC O
- O
MS O
/ O
MS O
spectra O
were O
used O
together O
to O
determine O
the O
structure O
of O
hitherto O
undescribed O
11oxo B
- I
pregnane I
( I
enes I
) I
. O

Our O
analysis O
suggests O
that O
fm O
is O
the O
major O
determinant O
of O
total O
drug O
M O
/ O
P O
ratio O
for O
amine B
, O
alcohol B
, O
N B
- I
and I
S I
- I
oxide I
, O
and O
carboxylic B
acid I
metabolites O
. O

It O
also O
contains O
the O
Pt B
( I
0 I
) I
Karstedt I
catalyst I
. O

Ni B
( I
II I
) I
- I
NTA I
Modified O
Poly B
( I
ethylene I
imine I
) I
Glycopolymers O
: O
Physicochemical O
Properties O
and O
First O
In O
Vitro O
Study O
of O
Polyplexes O
Formed O
with O
HIV O
- O
Derived O
Peptides O
. O

Here O
, O
we O
report O
that O
self O
- O
assembled O
monolayers O
of O
10 B
, I
12 I
- I
pentacosadiynoic I
acid I
( O
PCDA B
) O
on O
epitaxial O
graphene B
can O
be O
used O
to O
template O
the O
reaction O
and O
directed O
growth O
of O
atomic O
layer O
deposited O
( O
ALD O
) O
oxide B
nanostructures O
with O
sub O
- O
10 O
nm O
lateral O
resolution O
. O

Steroids B
Glycosylated O
with O
Both O
d B
- I
and I
l I
- I
Arabinoses I
from O
the O
South O
China O
Sea O
Gorgonian O
Dichotella O
gemmacea O
. O

These O
glycosides O
are O
found O
to O
have O
sugar B
moieties O
of O
both O
beta B
- I
l I
- I
and I
beta I
- I
d I
- I
arabinopyranoses I
by O
HPLC O
analysis O
of O
their O
thiocarbamoyl B
- I
thiazolidine I
derivatives O
and O
those O
of O
authentic O
d B
- I
and I
l I
- I
arabinoses I
, O
leading O
to O
the O
structure O
revision O
of O
junceelloside B
C I
( O
1 O
) O
. O

Human O
milk O
oligosaccharides O
contain O
a O
large O
variety O
of O
oligosaccharides O
, O
of O
which O
lacto B
- I
N I
- I
biose I
I I
( O
Gal B
- I
beta I
1 I
, I
3 I
- I
GlcNAc I
; O
LNB B
) O
predominates O
as O
a O
major O
core O
structure O
. O

Structural O
and O
dynamical O
properties O
of O
room O
- O
temperature O
ionic O
liquids O
containing O
the O
cation O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
( O
[ B
BMIM I
] I
( I
+ I
) I
) O
and O
three O
different O
anions O
( O
hexafluorophosphate B
, O
[ B
PF6 I
] I
( I
- I
) I
, O
tetrafluoroborate B
, O
[ B
BF4 I
] I
( I
- I
) I
, O
and O
bis B
( I
trifluoromethylsulfo I
) I
imide I
, O
[ B
NTf2 I
] I
( I
- I
) I
) O
doped O
with O
several O
molar O
fractions O
of O
lithium B
salts O
with O
a O
common O
anion O

Structural O
and O
dynamical O
properties O
of O
room O
- O
temperature O
ionic O
liquids O
containing O
the O
cation O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
( O
[ B
BMIM I
] I
( I
+ I
) I
) O
and O
three O
different O
anions O
( O
hexafluorophosphate B
, O
[ B
PF6 I
] I
( I
- I
) I
, O
tetrafluoroborate B
, O
[ B
BF4 I
] I
( I
- I
) I
, O
and O
bis B
( I
trifluoromethylsulfo I
) I
imide I
, O
[ B
NTf2 I
] I
( I
- I
) I
) O
doped O
with O
several O
molar O
fractions O
of O
lithium B
salts O
with O
a O
common O
anion O

Structural O
and O
dynamical O
properties O
of O
room O
- O
temperature O
ionic O
liquids O
containing O
the O
cation O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
( O
[ B
BMIM I
] I
( I
+ I
) I
) O
and O
three O
different O
anions O
( O
hexafluorophosphate B
, O
[ B
PF6 I
] I
( I
- I
) I
, O
tetrafluoroborate B
, O
[ B
BF4 I
] I
( I
- I
) I
, O
and O
bis B
( I
trifluoromethylsulfo I
) I
imide I
, O
[ B
NTf2 I
] I
( I
- I
) I
) O
doped O
with O
several O
molar O
fractions O
of O
lithium B
salts O
with O
a O
common O
anion O

Structural O
and O
dynamical O
properties O
of O
room O
- O
temperature O
ionic O
liquids O
containing O
the O
cation O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
( O
[ B
BMIM I
] I
( I
+ I
) I
) O
and O
three O
different O
anions O
( O
hexafluorophosphate B
, O
[ B
PF6 I
] I
( I
- I
) I
, O
tetrafluoroborate B
, O
[ B
BF4 I
] I
( I
- I
) I
, O
and O
bis B
( I
trifluoromethylsulfo I
) I
imide I
, O
[ B
NTf2 I
] I
( I
- I
) I
) O
doped O
with O
several O
molar O
fractions O
of O
lithium B
salts O
with O
a O
common O
anion O

The O
effect O
of O
the O
size O
of O
the O
salt O
cation O
was O
also O
analyzed O
by O
comparing O
these O
results O
with O
those O
for O
mixtures O
of O
[ B
BMIM I
] I
[ I
PF6 I
] I
with O
NaPF6 B
. O

Moreover O
, O
[ B
Li I
] I
( I
+ I
) I
and O
[ B
Na I
] I
( I
+ I
) I
cations O
were O
found O
to O
form O
bonded O
- O
like O
, O
long O
- O
lived O
aggregates O
with O
the O
anions O
in O
their O
first O
solvation O
shell O
, O
which O
act O
as O
very O
stable O
kinetic O
entities O
within O
which O
a O
marked O
rattling O
motion O
of O
salt O
ions O
takes O
place O
. O

Moreover O
, O
[ B
Li I
] I
( I
+ I
) I
and O
[ B
Na I
] I
( I
+ I
) I
cations O
were O
found O
to O
form O
bonded O
- O
like O
, O
long O
- O
lived O
aggregates O
with O
the O
anions O
in O
their O
first O
solvation O
shell O
, O
which O
act O
as O
very O
stable O
kinetic O
entities O
within O
which O
a O
marked O
rattling O
motion O
of O
salt O
ions O
takes O
place O
. O

Interestingly O
, O
the O
specificity O
determination O
unveiled O
a O
new O
layer O
of O
complexity O
where O
the O
enzymes O
not O
only O
have O
specificity O
for O
5 B
- I
beta I
- I
glucosylated I
hmC I
( O
5 B
beta I
ghmC I
) O
but O
also O
5 B
- I
alpha I
- I
glucosylated I
hmC I
( O
5 B
alpha I
ghmC I
) O
. O

Interestingly O
, O
the O
specificity O
determination O
unveiled O
a O
new O
layer O
of O
complexity O
where O
the O
enzymes O
not O
only O
have O
specificity O
for O
5 B
- I
beta I
- I
glucosylated I
hmC I
( O
5 B
beta I
ghmC I
) O
but O
also O
5 B
- I
alpha I
- I
glucosylated I
hmC I
( O
5 B
alpha I
ghmC I
) O
. O

Four O
ruthenium B
( I
ii I
) I
asymmetric O
complexes O
, O
[ B
Ru I
( I
bpy I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
PAIDH B
= O
2 B
- I
pyridyl I
- I
1H I
- I
anthra I
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
, O
) O
, O
[ B
Ru I
( I
phen I
) I
2 I
( I
PAIDH I
) I
] I
( I
2 I
+ I
) I
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
) O
, O
[ B
Ru I
( I
dmp I
) I
2 I
( I

Polybrominated B
Dibenzo I
- I
p I
- I
dioxins I
( O
PBDDs B
) O
, O
Dibenzofurans B
( O
PBDFs B
) O
and O
Biphenyls B
( O
PBBs B
) O
- O
Inclusion O
in O
the O
Toxicity O
Equivalency O
Factor O
Concept O
for O
Dioxin B
- O
like O
Compounds O
- O

The O
expert O
panel O
concluded O
that O
polybrominated B
dibenzo I
- I
p I
- I
dioxins I
( O
PBDDs B
) O
, O
dibenzofurans B
( O
PBDFs B
) O
, O
and O
some O
dioxin B
- O
like O
biphenyls B
( O
dl O
- O
PBBs B
) O
may O
contribute O
significantly O
in O
daily O
human O
background O
exposure O
to O
the O
total O
dioxin B
toxic O
equivalencies O
( O
TEQs O
) O
. O

Furthermore O
, O
the O
( B
22R I
) I
- I
spirosolanol I
glycoside I
( O
11 O
) O
selectively O
induced O
apoptosis O
in O
A549 O
cells O
without O
affecting O
the O
caspase O
- O
3 O
activity O
level O
. O

We O
find O
the O
SLOS O
mouse O
has O
reduced O
levels O
of O
cholesterol B
and O
desmosterol B
and O
increased O
levels O
of O
7 B
- I
and I
8 I
- I
dehydrocholesterol I
and O
of O
7 B
- I
and I
8 I
- I
dehydrodesmosterol I
in O
brain O
compared O
to O
the O
wild O
type O
. O

We O
find O
the O
SLOS O
mouse O
has O
reduced O
levels O
of O
cholesterol B
and O
desmosterol B
and O
increased O
levels O
of O
7 B
- I
and I
8 I
- I
dehydrocholesterol I
and O
of O
7 B
- I
and I
8 I
- I
dehydrodesmosterol I
in O
brain O
compared O
to O
the O
wild O
type O
. O

NF O
- O
kappa O
B O
reporter O
- O
, O
EROD O
- O
, O
SELE O
- O
, O
12 B
( I
S I
) I
- I
HETE I
- O
and O
adhesion O
assays O
were O
performed O
to O
investigate O
the O
anti O
- O
metastatic O
properties O
of O
xanthohumol B
. O

A O
metal O
- O
organic O
framework O
( O
MOF O
) O
bearing O
the O
aqua B
- I
hydroxo I
species O
( B
O2H3 I
) I
( I
- I
) I
in O
the O
framework O
, O
as O
well O
as O
the O
processes O
that O
govern O
the O
equilibrium O
aqua B
- I
hydroxo I
( B
O2H3 I
) I
( I
- I
) I
< O
- O
- O
> O
hydroxyl B
( O
OH B
) O
in O
Sc B
- O
MOFs O
, O
are O
studied O
experimentally O
and O
theoretically O
. O

A O
metal O
- O
organic O
framework O
( O
MOF O
) O
bearing O
the O
aqua B
- I
hydroxo I
species O
( B
O2H3 I
) I
( I
- I
) I
in O
the O
framework O
, O
as O
well O
as O
the O
processes O
that O
govern O
the O
equilibrium O
aqua B
- I
hydroxo I
( B
O2H3 I
) I
( I
- I
) I
< O
- O
- O
> O
hydroxyl B
( O
OH B
) O
in O
Sc B
- O
MOFs O
, O
are O
studied O
experimentally O
and O
theoretically O
. O

The O
thermodynamically O
more O
stable O
[ B
Sc3 I
( I
3 I
, I
5 I
- I
DSB I
) I
2 I
( I
mu I
- I
O2H3 I
) I
( I
mu I
- I
OH I
) I
2 I
( I
H2O I
) I
2 I
] I
( O
from O
now O
on O
, O
( B
O2H3 I
) I
Sc I
- O
MOF O
; O
3 B
, I
5 I
- I
DSB I
= O
3 B
, I
5 I
- I
disulfobenzoic I
acid I
) O
was O
obtained O
as O
a O
pure O
and O
stable O
phase O
. O

Injectable O
aqueous O
solutions O
of O
thiolated B
poly I
( I
aspartic I
acid I
) I
can O
be O
converted O
into O
mechanically O
stable O
gels O
by O
oxidation O
, O
which O
can O
be O
useful O
for O
drug O
encapsulation O
and O
targeted O
delivery O
. O

Discovery O
of O
3 B
, I
3 I
' I
- I
diindolylmethanes I
as O
potent O
antileishmanial O
agents O
. O

An O
efficient O
protocol O
for O
synthesis O
of O
3 B
, I
3 I
' I
- I
diindolylmethanes I
using O
recyclable O
Fe B
- O
pillared O
interlayered O
clay O
( O
Fe B
- O
PILC O
) O
catalyst O
under O
aqueous O
medium O
has O
been O
developed O
. O

All O
synthesized O
3 B
, I
3 I
' I
- I
diindolylmethanes I
showed O
promising O
antileishmanial O
activity O
against O
Leishmania O
donovani O
promastigotes O
as O
well O
as O
axenic O
amastigotes O
. O

Further O
, O
a O
pharmacophore O
based O
QSAR O
model O
was O
established O
to O
understand O
the O
crucial O
molecular O
features O
of O
3 B
, I
3 I
' I
- I
diindolylmethanes I
essential O
for O
potent O
antileishmanial O
activity O
. O

Developed O
synthetic O
protocol O
will O
be O
useful O
for O
economical O
and O
eco O
- O
friendly O
synthesis O
of O
potent O
antileishmanial O
and O
antifungal O
3 B
, I
3 I
' I
- I
diindolylmethane I
class O
of O
compounds O
. O

In O
silico O
identification O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
- O
1 O
inhibitors O
and O
their O
chemosensitizing O
effects O
against O
cisplatin B
- O
resistant O
human O
gastric O
cancer O
cells O
. O

Poly B
( I
ADP I
- I
ribose I
) I
polymerase O
- O
1 O
( O
PARP O
- O
1 O
) O
enzyme O
is O
involved O
in O
the O
repair O
of O
DNA O
damages O
made O
by O
certain O
anticancer O
agents O
. O

Our O
results O
show O
that O
PARP O
- O
1 O
inhibitors O
suppress O
the O
formation O
of O
poly B
( I
ADP I
- I
ribose I
) I
and O
enhance O
the O
cytotoxicity O
of O
cisplatin B
. O

Diagnostic O
performance O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
predicting O
the O
malignancy O
of O
thyroid O
nodules O
: O
a O
meta O
- O
analysis O
. O

Several O
studies O
have O
investigated O
the O
diagnostic O
performance O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
the O
evaluation O
of O
thyroid O
nodules O
suspicious O
for O
malignancy O
with O
conflicting O
results O
. O

A O
comprehensive O
literature O
search O
of O
studies O
published O
through O
December O
2012 O
regarding O
the O
diagnostic O
performance O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
the O
evaluation O
of O
thyroid O
nodules O
suspicious O
for O
malignancy O
was O
carried O
out O
. O

Pooled O
sensitivity O
and O
specificity O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
on O
a O
per O
lesion O
- O
based O
analysis O
and O
the O
area O
under O
the O
ROC O
curve O
were O
calculated O
. O

Pooled O
sensitivity O
and O
specificity O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
detecting O
malignant O
thyroid O
nodules O
were O
85 O
. O
1 O
% O
[ O
95 O
% O
confidence O
interval O
( O
95 O
% O
CI O
) O
: O
81 O
. O
1 O
- O
88 O
. O
5 O
% O
] O
and O
45 O
. O
7 O
% O
( O
95 O
% O
CI O
: O
42 O
. O
7 O
- O
48 O
. O
7 O
% O
) O
, O
respectively O
, O
on O
a O
per O
lesion O
- O
based O
analysis O
, O
irrespective O
of O
eventual O
results O
of O
previous O
technetium B
pertechnetate I
( O
( B
99m I
) I
TcO4 I
) O
or O
iodine B
- I
123 I
( O
( B
123 I
) I
I I
) O
scan O
. O

A O
sub O
- O
analysis O
restricted O
to O
data O
on O
hypofunctioning O
nodules O
on O
( B
99m I
) I
TcO4 I
or O
( B
123 I
) I
I I
scans O
was O
performed O
: O
pooled O
sensitivity O
and O
specificity O
of O
( B
99m I
) I
Tc I
- I
MIBI I
scan O
in O
these O
nodules O
were O
82 O
. O
1 O
% O
( O
95 O
% O
CI O
: O
77 O
. O
2 O
- O
86 O
. O
3 O
% O
) O
and O
62 O
. O
8 O
% O
( O
95 O
% O
CI O
: O
58 O
. O
9 O
- O
66 O
. O
7 O
% O
) O
, O
respectively O
, O
on O
a O
per O
lesion O
- O
based O
analysis O
. O

( B
99m I
) I
Tc I
- I
MIBI I
scan O
is O
a O
sensitive O
diagnostic O
tool O
in O
predicting O
the O
malignancy O
of O
thyroid O
nodules O
. O

In O
the O
current O
study O
, O
we O
crossed O
mdr1a O
. O
fLUC O
mice O
into O
the O
pxr O
knockout O
( O
pxr O
( O
- O
/ O
- O
) O
) O
genetic O
background O
and O
injected O
mice O
with O
pregnenolone B
- I
16 I
alpha I
- I
carbonitrile I
( O
PCN B
) O
, O
a O
strong O
PXR O
ligand O
, O
and O
two O
therapeutically O
relevant O
taxanes B
, O
paclitaxel B
and O
docetaxel B
. O

The O
highly O
reactive O
conjugated O
aldehydes B
( O
alpha B
, I
beta I
- I
unsaturated I
aldehydes I
and O
2 B
, I
3 I
- I
epoxyaldehydes I
) O
are O
sensitizing O
moieties O
, O
while O
nonconjugated O
aldehydes B
and O
nonterminal O
aliphatic O
epoxides B
show O
low O
reactivity O
and O
low O
sensitization O
potency O
. O

The O
polyphenol B
( B
- I
) I
- I
epigallocatechin I
gallate I
( O
EGCG B
) O
was O
recently O
reported O
to O
inhibit O
A O
beta O
fibrillization O
and O
redirect O
A O
beta O
aggregation O
into O
unstructured O
, O
off O
- O
pathway O
oligomers O
. O

Then O
, O
the O
PEG B
- O
grafted O
cellulose O
nanofibril O
/ O
chloroform B
dispersion O
and O
poly B
( I
l I
- I
lactide I
) I
( O
PLLA B
) O
/ O
chloroform B
solution O
were O
mixed O
, O
and O
the O
PEG B
- O
grafted O
cellulose O
nanofibril O
/ O
PLLA B
composite O
films O
with O
various O
blend O
ratios O
were O
prepared O
by O
casting O
the O
mixtures O
on O
a O
plate O
and O
drying O
. O

The O
fragment O
indole B
- I
6 I
- I
carboxylic I
acid I
( O
1F1 O
) O
, O
previously O
identified O
as O
a O
flap O
site O
binder O
in O
a O
fragment O
- O
based O
screen O
against O
HIV O
protease O
( O
PR O
) O
, O
has O
been O
cocrystallized O
with O
pepstatin B
- O
inhibited O
PR O
and O
with O
apo O
- O
PR O
. O

In O
three O
- O
dimensional O
( O
3D O
) O
cell O
cultures O
consisting O
of O
MCF O
- O
7 O
breast O
cancer O
cell O
spheroids O
that O
were O
placed O
on O
lymph O
- O
endothelial O
cell O
( O
LEC O
) O
monolayers O
, O
tumour O
cell O
spheroids O
induce O
" O
circular O
chemorepellent O
- O
induced O
defects O
" O
( O
CCIDs O
) O
in O
the O
LEC O
monolayer O
; O
12 B
( I
S I
) I
- I
Hydroxyeicosatetraen I
acid I
( O
12 B
( I
S I
) I
- I
HETE I
) O
and O
NF O
- O
kappa O
B O
activity O
are O
major O
factors O
inducing O
CCIDs O
, O
which O
are O
entry O
gates O
for O
tumour O
emboli O

Furthermore O
, O
Western O
blot O
analyses O
, O
NF O
- O
kappa O
B O
reporter O
, O
EROD O
, O
SELE O
, O
12 B
( I
S I
) I
- I
HETE I
, O
and O
adhesion O
assays O
were O
performed O
to O
investigate O
the O
properties O
of O
heteronemin B
. O

Furthermore O
, O
heteronemin B
reduced O
the O
adhesion O
of O
MCF O
- O
7 O
cells O
to O
LECs O
and O
suppressed O
12 B
( I
S I
) I
- I
HETE I
- O
induced O
expression O
of O
the O
EMT O
marker O
paxillin O
, O
which O
is O
a O
regulator O
of O
directional O
cell O
migration O
. O

The O
consumption O
of O
n B
- I
3 I
polyunsaturated I
fatty I
acids I
differentially O
modulates O
gene O
expression O
of O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
and O
gamma O
and O
hypoxia O
- O
inducible O
factor O
1 O
alpha O
in O
subcutaneous O
adipose O
tissue O
of O
obese O
adolescents O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
long O
- O
chain O
omega B
- I
3 I
polyunsaturated I
fatty I
acid I
( O
n B
- I
3 I
PUFA I
) O
supplementation O
on O
metabolic O
state O
and O
gene O
expression O
in O
subcutaneous O
adipose O
tissues O
of O
obese O
adolescents O
. O

Inspired O
by O
Pearson O
' O
s O
hard O
and O
soft O
acid O
- O
base O
( O
HSAB O
) O
principle O
, O
uniform O
amorphous O
Ni B
( I
OH I
) I
2 I
nanoboxes O
with O
intact O
shell O
structures O
and O
various O
sizes O
are O
quickly O
fabricated O
by O
deliberately O
selecting O
S2 B
O3 I
( I
2 I
- I
) I
as O
the O
coordinating O
etchant O
toward O
Cu2 B
O I
templates O
and O
optimizing O
the O
reaction O
conditions O
. O

Anticancer O
activity O
of O
the O
liposome O
- O
encapsulated O
cyclic B
dipeptides I
, O
cyclo B
( I
His I
- I
Gly I
) I
and O
cyclo B
( I
His I
- I
Ala I
) I
. O

Anticancer O
activity O
of O
the O
liposome O
- O
encapsulated O
cyclic B
dipeptides I
, O
cyclo B
( I
His I
- I
Gly I
) I
and O
cyclo B
( I
His I
- I
Ala I
) I
. O

Cyclo B
( I
His I
- I
Gly I
) I
and O
cyclo B
( I
His I
- I
Ala I
) I
have O
also O
recently O
demonstrated O
significant O
anticancer O
activity O
against O
a O
range O
of O
cell O
lines O
, O
however O
, O
as O
a O
result O
of O
their O
physicochemistry O
, O
namely O
high O
solubility O
and O
low O
lipophilicity O
, O
it O
can O
be O
predicted O
that O
cellular O
permeability O
would O
be O
low O
, O
making O
them O
ideal O
candidates O
for O
liposome O
drug O
delivery O
. O

Cyclo B
( I
His I
- I
Gly I
) I
and O
cyclo B
( I
His I
- I
Ala I
) I
have O
also O
recently O
demonstrated O
significant O
anticancer O
activity O
against O
a O
range O
of O
cell O
lines O
, O
however O
, O
as O
a O
result O
of O
their O
physicochemistry O
, O
namely O
high O
solubility O
and O
low O
lipophilicity O
, O
it O
can O
be O
predicted O
that O
cellular O
permeability O
would O
be O
low O
, O
making O
them O
ideal O
candidates O
for O
liposome O
drug O
delivery O
. O

However O
, O
modification O
of O
the O
polyethylene B
glycol I
with O
folic B
acid I
to O
target O
folate O
receptors O
significantly O
decreased O
the O
IC50 O
values O
recorded O
in O
all O
cells O
lines O
tested O
, O
particularly O
HeLa O
cells O
cultured O
in O
media O
containing O
physiological O
concentrations O
of O
folic B
acid I
with O
the O
lowest O
IC50 O
being O
recorded O
as O
0 O
. O
0962 O
mM O
for O
folate B
- O
targeted O
cyclo B
( I
His I
- I
Ala I
) I
. O

The O
production O
from O
glycerol B
of O
succinic B
, I
acetic I
, I
citric I
, I
malic I
and I
oxalic I
acids I
from O
C O
. O
oleophila O
and O
W O
. O
anomalus O
, O
and O
that O
of O
succinic B
, I
oxalic I
and I
acetic I
acids I
by O
P O
. O
fermentans O
is O
reported O
for O
the O
first O
time O
in O
this O
work O
, O
as O
is O
the O
production O
of O
oxalic B
acid I
from O
glycerol B
in O
yeasts O
. O

Encapsulation O
of O
indole B
- I
3 I
- I
carbinol I
and O
3 B
, I
3 I
' I
- I
diindolylmethane I
in O
zein O
/ O
carboxymethyl B
chitosan O
nanoparticles O
with O
controlled O
release O
property O
and O
improved O
stability O
. O

Indole B
- I
3 I
- I
carbinol I
( O
I3C B
) O
and O
3 B
, I
3 I
' I
- I
diindolylmethane I
( O
DIM B
) O
are O
two O
bioactive O
compounds O
from O
Cruciferous O
vegetables O
. O

Triple O
quadrupole O
LC O
/ O
MS O
and O
Q O
- O
TOF O
LC O
/ O
MS O
analyses O
revealed O
four O
major O
anthocyanins B
; O
cyanidin B
3 I
- I
O I
- I
sambubioside I
, O
cyanidin B
3 I
- I
O I
- I
glucoside I
, O
cyanidin B
3 I
- I
O I
- I
xylosylrutinoside I
, O
and O
cyanidin B
3 I
- I
O I
- I
rutinoside I
in O
increasing O
order O
of O
amounts O
. O

Triple O
quadrupole O
LC O
/ O
MS O
and O
Q O
- O
TOF O
LC O
/ O
MS O
analyses O
revealed O
four O
major O
anthocyanins B
; O
cyanidin B
3 I
- I
O I
- I
sambubioside I
, O
cyanidin B
3 I
- I
O I
- I
glucoside I
, O
cyanidin B
3 I
- I
O I
- I
xylosylrutinoside I
, O
and O
cyanidin B
3 I
- I
O I
- I
rutinoside I
in O
increasing O
order O
of O
amounts O
. O

Triple O
quadrupole O
LC O
/ O
MS O
and O
Q O
- O
TOF O
LC O
/ O
MS O
analyses O
revealed O
four O
major O
anthocyanins B
; O
cyanidin B
3 I
- I
O I
- I
sambubioside I
, O
cyanidin B
3 I
- I
O I
- I
glucoside I
, O
cyanidin B
3 I
- I
O I
- I
xylosylrutinoside I
, O
and O
cyanidin B
3 I
- I
O I
- I
rutinoside I
in O
increasing O
order O
of O
amounts O
. O

Triple O
quadrupole O
LC O
/ O
MS O
and O
Q O
- O
TOF O
LC O
/ O
MS O
analyses O
revealed O
four O
major O
anthocyanins B
; O
cyanidin B
3 I
- I
O I
- I
sambubioside I
, O
cyanidin B
3 I
- I
O I
- I
glucoside I
, O
cyanidin B
3 I
- I
O I
- I
xylosylrutinoside I
, O
and O
cyanidin B
3 I
- I
O I
- I
rutinoside I
in O
increasing O
order O
of O
amounts O
. O

Oleic B
, I
linoleic I
and I
linolenic I
acids I
were O
the O
major O
unsaturated B
fatty I
acids I
found O
. O

The O
silica B
nanoparticles O
were O
modified O
with O
( B
3 I
- I
chloropropyl I
) I
trimethoxysilan I
and O
polyethylenimine B
, O
respectively O
, O
and O
polymerised O
to O
form O
the O
TICSNs O
with O
ethylene B
glycol I
dimethacrylate I
as O
cross O
- O
linker O
. O

In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine B
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase O
- O
9 O
and O
3 O
, O
and O
cleavage O
of O
Poly B
( I
ADP I
- I
ribose I
) I
- O
Polymerase O
. O

Synthesis O
and O
biological O
evaluation O
of O
novel O
aliphatic B
amido I
- I
quaternary I
ammonium I
salts I
for O
anticancer O
chemotherapy O
: O
Part O
II O
. O

A O
series O
of O
novel O
aliphatic B
amido I
- I
quaternary I
ammonium I
salts I
were O
synthesized O
and O
evaluated O
for O
their O
anticancer O
effects O
involving O
induction O
of O
RhoB O
. O

Most O
of O
these O
compounds O
, O
featuring O
open O
- O
ring O
forms O
of O
aliphatic B
amido I
- I
quaternary I
ammonium I
salts I
, O
exhibited O
potent O
anti O
- O
proliferative O
activities O
in O
human O
cancer O
cell O
lines O
, O
including O
PC O
- O
3 O
, O
NUGC O
- O
3 O
, O
MDA O
- O
MB O
- O
231 O
, O
ACHN O
, O
HCT O
- O
15 O
, O
and O
NCI O
- O
H23 O
. O

Data O
on O
base O
excision O
repair O
( O
BER O
) O
, O
direct O
reversal O
with O
O B
( I
6 I
) I
- I
alkylguanine I
transferase O
and O
double O
strand O
breaks O
repair O
, O
although O
rather O
scarce O
, O
are O
being O
reviewed O
, O
as O
well O
as O
nucleotide B
excision O
repair O
( O
NER O
) O
and O
photoreactivation O
repair O
( O
PER O
) O
, O
which O
are O
by O
far O
the O
most O
studied O
repair O
mechanisms O
in O
fish O
. O

Furthermore O
, O
UGT1A9 O
and O
2B7 O
were O
the O
predominant O
UGT O
isoforms O
responsible O
for O
R B
- I
and I
S I
- I
ornidazole I
glucuronidation O
in O
humans O
, O
respectively O
. O

Three O
metal O
complexes O
consisting O
of O
Li B
( I
+ I
) I
, O
Zn B
( I
2 I
+ I
) I
, O
and O
Al B
( I
3 I
+ I
) I
and O
quinolinol B
- I
functionalized I
l I
- I
glutamides I
( O
HQLG B
) O
, O
( O
abbreviated O
as O
LiHQLG B
, O
Zn B
( I
HQLG I
) I
2 I
, O
and O
Al B
( I
HQLG I
) I
3 I
) O
were O
found O
to O
form O
fluorescent O
metallogels O
in O
several O
organic O
solvents O
. O

Reactions O
of O
nickel B
oxide I
cluster O
ions O
, O
NinOn B
+ I
x I
( I
+ I
) I
( O
n O
= O
4 O
- O
10 O
, O
x O
= O
- O
1 O
~ O
+ O
3 O
) O
, O
with O
CO B
in O
a O
He B
buffer O
gas O
were O
investigated O
using O
mass O
spectrometry O
. O

When O
the O
cluster O
ions O
react O
at O
room O
temperature O
, O
a O
CO B
molecule O
tends O
to O
attach O
readily O
to O
NinOn B
+ I
x I
( I
+ I
) I
for O
all O
of O
the O
cluster O
ions O
with O
different O
stoichiometry O
, O
although O
rate O
constants O
of O
the O
CO B
attachment O
reaction O
are O
more O
or O
less O
stoichiometry O
- O
dependent O
. O

This O
finding O
is O
interpreted O
such O
that O
the O
CO B
molecule O
that O
physisorbs O
weakly O
to O
NinOn B
+ I
x I
( I
+ I
) I
at O
room O
temperature O
desorbs O
into O
the O
gas O
phase O
by O
the O
post O
heating O
. O

The O
sensitivity O
difference O
of O
trans B
- I
and I
cis I
- I
diethylstilbestrol I
( O
isomerizing O
in O
sample O
preparation O
processes O
) O
by O
the O
LC O
/ O
MS O
was O
measured O
by O
running O
a O
trans O
/ O
cis O
mixture O
( O
ratio O
measured O
by O
a O
quantitative O
NMR O
) O
with O
and O
without O
sample O
matrices O
, O
and O
applied O
for O
the O
determination O
of O
total O
diethylstilbestrol B
. O

In O
these O
last O
samples O
, O
alpha B
- I
terpineol I
, O
hotrienol B
, O
nerol B
oxide I
, O
furanic B
linalool I
oxides I
A I
/ I
B I
and O
rose B
oxide I
concentrations O
significantly O
increased O
. O

Two O
monomers O
that O
undergo O
different O
click O
reactions O
, O
pentafluorophenyl B
acrylate I
( O
PFPA B
) O
and O
4 B
- I
( I
trimethylsilyl I
) I
ethynylstyrene I
( O
TMSES B
) O
, O
were O
sequentially O
polymerized O
from O
a O
silicon B
surface O
in O
the O
presence O
of O
a O
shadowmask O
with O
UV O
light O
, O
generating O
12 O
. O
5 O
and O
62 O
mu O
m O
pitch O
patterns O
. O

A O
novel O
series O
of O
10 B
- I
hydroxyl I
ketolide I
derivatives O
were O
synthesized O
, O
during O
which O
a O
distinctive O
intermediate O
, O
3 B
- I
O I
- I
descladinosyl I
- I
3 I
- I
oxo I
- I
11 I
- I
deoxy I
- I
10 I
, I
11 I
- I
epoxy I
- I
6 I
- I
O I
- I
methylerythromycin I
A I
, O
was O
obtained O
from O
6 B
- I
O I
- I
methylerythromycin I
A I
. O

The O
synthesis O
of O
novel O
pyrimidine B
deoxyapiothionucleos I
of O
d O
- O
and O
l O
- O
series O
was O
realized O
following O
application O
of O
a O
versatile O
and O
high O
- O
yielding O
scheme O
, O
which O
utilized O
inexpensive O
l B
- I
and I
d I
- I
arabinose I
as O
starting O
materials O
, O
respectively O
, O
and O
which O
makes O
use O
of O
a O
regio O
- O
and O
stereo O
- O
selective O
Pummerer O
rearrangement O
reaction O
for O
the O
coupling O
of O
the O
nucleobase B
with O
the O
thiosugar B
moiety O
. O

Catecholamine B
mimetic O
EDTA B
- I
bis I
( I
tyramide I
) I
was O
synthesized O
and O
characterized O
by O
various O
spectroscopic O
techniques O
( O
NMR O
, O
Mass O
spectroscopy O
) O
and O
lambda O
em O
310 O
nm O
for O
the O
excitation O
at O
270 O
nm O
. O

Finally O
, O
EDTA B
- I
bis I
( I
tyramide I
) I
labeled O
with O
( B
99m I
) I
Tc I
to O
investigate O
its O
in O
- O
vivo O
radiopharmaceutical O
efficiency O
, O
having O
97 O
% O
binding O
affinity O
with O
98 O
% O
radiochemical O
purity O
. O

High O
throughput O
screening O
identified O
the O
pyrazole B
- I
4 I
- I
acetic I
acid I
substructure O
as O
CRTh2 O
receptor O
antagonists O
. O

CONCLUSIONS O
: O
Collectively O
, O
the O
present O
results O
suggest O
that O
the O
ethanol B
extract O
of O
Caesalpinia O
pyramidalis O
produced O
dose O
- O
related O
antinociception O
in O
several O
models O
of O
pain O
through O
mechanisms O
that O
involved O
both O
glutamatergic O
system O
and O
/ O
or O
the O
l B
- I
arginine I
- I
nitric I
oxide I
pathway O
, O
supporting O
the O
folkloric O
usage O
of O
the O
plant O
to O
treat O
various O
painful O
processes O
. O

Early O
data O
indicated O
that O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
) O
inhibitors O
exploiting O
the O
concept O
of O
synthetic O
lethality O
would O
offer O
improved O
outcomes O
for O
patients O
with O
ER O
- O
negative O
, O
progesterone B
receptor O
( O
PR O
) O
- O
negative O
, O
HER2 O
- O
negative O
breast O
cancer O
often O
referred O
to O
as O
triple O
negative O
breast O
cancer O
( O
TNBC O
) O
; O
however O
, O
data O
in O
the O
phase O
III O
setting O
failed O
to O
confirm O
these O
findings O
but O
this O
may O
be O
because O
the O
drug O
was O
not O
a O
true O
PARP O
inhibitor O
. O

Antimicrobial O
and O
demelanizing O
activity O
of O
Ganoderma O
lucidum O
extract O
, O
p B
- I
hydroxybenzoic I
and I
cinnamic I
acids I
and O
their O
synthetic O
acetylated B
glucuronide I
methyl I
esters I
. O

Herein O
, O
it O
is O
described O
the O
synthesis O
of O
protected O
( O
acetylated O
) O
glucuronide O
derivatives O
of O
p B
- I
hydroxybenzoic I
and I
cinnamic I
acids I
, O
two O
compounds O
identified O
in O
the O
medicinal O
mushroom O
Ganoderma O
lucidum O
. O

p B
- I
Hydroxybenzoic I
and I
cinnamic I
acids I
, O
as O
also O
their O
protected O
glucuronide O
derivatives O
revealed O
high O
antimicrobial O
( O
antibacterial O
and O
antifungal O
) O
activity O
, O
even O
better O
than O
the O
one O
showed O
by O
commercial O
standards O
. O

In O
the O
present O
study O
, O
in O
situ O
microcosms O
consisting O
of O
activated O
carbon B
pellets O
( O
BACTRAP O
( O
R O
) O
s O
) O
were O
loaded O
with O
either O
( B
13 I
) I
C I
- I
naphthalene I
or O
( B
13 I
) I
C I
- I
fluorene I
and O
were O
subsequently O
exposed O
in O
the O
contaminant O
source O
and O
plume O
fringe O
region O
of O
an O
PAH B
contaminated O
aquifer O
. O

In O
the O
present O
study O
, O
in O
situ O
microcosms O
consisting O
of O
activated O
carbon B
pellets O
( O
BACTRAP O
( O
R O
) O
s O
) O
were O
loaded O
with O
either O
( B
13 I
) I
C I
- I
naphthalene I
or O
( B
13 I
) I
C I
- I
fluorene I
and O
were O
subsequently O
exposed O
in O
the O
contaminant O
source O
and O
plume O
fringe O
region O
of O
an O
PAH B
contaminated O
aquifer O
. O

Rationale O
for O
the O
higher O
reactivity O
of O
interfacial O
sites O
in O
methanol B
decomposition O
on O
Au13 B
/ I
TiO2 I
( I
110 I
) I
. O

We O
find O
that O
the O
higher O
activity O
of O
interfacial O
sites O
in O
Au13 B
/ I
TiO2 I
( I
110 I
) I
towards O
methanol B
decomposition O
originates O
from O
charge O
- O
transfer O
- O
induced O
Coulomb O
interaction O
among O
the O
gold O
, O
reactant O
, O
and O
reducible O
TiO2 B
support O
, O
brought O
about O
through O
the O
formation O
of O
an O
ionic O
O B
- I
Au I
bond O
between O
gold O
and O
methoxy B
in O
such O
sites O
, O
which O
turns O
the O
participating O
perimeter O
gold O
atom O
cationic O
. O

More O
generally O
, O
our O
proposed O
mechanism O
for O
the O
reactivity O
of O
the O
gold O
/ O
TiO2 B
interface O
should O
hold O
for O
oxidation O
of O
organic O
molecules O
with O
the O
structure O
of O
R B
- I
O I
- I
R I
' I
, O
where O
R O
and O
R O
' O
are O
( B
saturated I
) I
hydrocarbons I
. O

Antiproliferative O
activity O
of O
2 B
, I
3 I
- I
disubstituted I
indoles I
toward O
apoptosis O
- O
resistant O
cancers O
cells O
. O

We O
describe O
a O
series O
of O
2 B
, I
3 I
- I
disubstituted I
indoles I
, O
which O
display O
cytostatic O
rather O
than O
cytotoxic O
effects O
in O
cancer O
cells O
, O
and O
serve O
as O
a O
new O
chemical O
scaffold O
to O
develop O
anticancer O
agents O
capable O
of O
combating O
apoptosis O
- O
resistant O
cancers O
associated O
with O
dismal O
prognoses O
. O

Apoptosis O
was O
evaluated O
using O
various O
methods O
including O
a O
terminal O
deoxyribonucleotide B
transferase O
- O
mediated O
deoxyuridine B
triphosphate I
nick O
- O
end O
labeling O
analysis O
kit O
and O
Western O
blotting O
for O
cleaved O
caspase O
3 O
, O
cleaved O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
and O
Bcl O
- O
xL O
. O

Whole O
blood O
collagen O
- O
induced O
platelet O
aggregation O
and O
calcium B
- O
induced O
thromboxane B
B2 I
( O
TxB2 B
) O
, O
aortic O
6 B
- I
keto I
- I
prostaglandin I
F1 I
alpha I
( O
6 B
- I
keto I
- I
PGF1 I
alpha I
) O
and O
nitrites B
+ O
nitrates B
, O
plasma O
concentration O
of O
lipid O
peroxides B
( O
TBARS O
) O
and O
red O
blood O
cell O
content O
of O
reduced B
glutathione I
( O
GSH B
) O
were O
measured O
. O

The O
aortic O
production O
of O
6 B
- I
keto I
- I
PGF1 I
alpha I
was O
unaltered O
except O
in O
the O
group O
treated O
with O
the O
dodecyl B
derivative O
. O

A O
novel O
copper B
( I
I I
) I
Schiff I
base I
complex O
has O
been O
synthesized O
and O
fully O
characterized O
by O
spectral O
, O
analytical O
and O
structural O
modes O
. O

